JNJ
Another analyst, same J&J glow-up
Johnson & Johnson is getting the post-earnings treatment: Guggenheim reiterated a Buy rating and set a $244 price target after the company’s first-quarter 2026 results. In analyst-land, that’s the equivalent of saying, “Yep, still looks good from here.”
Why the Street is leaning in
J&J’s Q1 numbers gave bulls enough to chew on:
- Sales: $24.06 billion, ahead of the $23.61 billion consensus
- EPS: $2.70, basically right in line with the $2.68 estimate
That combo is usually catnip for analysts who want proof the machine is still humming without a big drama headline attached. No fireworks, just a steady beat-and-keep-moving kind of quarter.
What it means for your portfolio
The big thing here isn’t just that one firm liked the quarter. It’s that J&J keeps collecting validation after results that weren’t flashy, but were solid enough to keep the Street comfortable. That matters because stocks like this often trade on whether the market believes the business can keep delivering boring-but-beautiful growth.
Big picture: J&J is looking less like a sleepy mega-cap and more like a company the analysts are still happy to pay up for.